Eli Lilly And Company ((LLY)), Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company, in collaboration with Incyte Corporation, recently updated their clinical study on Baricitinib, a treatment for rheumatoid arthritis. Officially titled ‘A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis,’ the study aims to compare the safety of Baricitinib against tumor necrosis factor (TNF) inhibitors, focusing on venous thromboembolic events (VTEs).
The study tests two doses of Baricitinib, administered orally, against TNF inhibitors like Adalimumab or Etanercept, which are given subcutaneously. The goal is to determine which treatment is safer for patients with rheumatoid arthritis.
This interventional study follows a randomized, parallel-group design with no masking, primarily aimed at treatment evaluation. It provides a direct comparison between Baricitinib and TNF inhibitors.
Key dates include the study’s start on April 25, 2019, and its completion, with the last update submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data analysis.
The study’s outcome could significantly impact Eli Lilly and Incyte’s stock performance, as positive results may enhance investor confidence and market position against competitors in the rheumatoid arthritis treatment space.
The study is completed, with further details available on the ClinicalTrials portal.